Immunogen Inc. announced that the US Food and Drug Administration has granted an accelerated approval for ELAHERETM for the treatment of adult patients with folate receptor alpha positive, platinum resistant epithelial ovarian fallopian tube or primary peritoneal cancer who have received one to three prior systemic therapy regimens.
BioNTech SE reported data from its ongoing first-in-human Phase 1/2 study evaluating the safety and preliminary efficacy of the company's new CAR-T cell therapy candidate, BNT211, in patients with advanced solid tumours. Preliminary results showed an encouraging safety profile and antitumor activity in patients with testicular cancer at the first dose levels of BNT211 evaluated.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5255
Published Date: Sep 25, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing prevalence of germ cell tumor, the growing geriatric population are some of the major factors anticipated to drive the growth of the germ cell tumor market.
The market is anticipated to attain a CAGR of ~12% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are Baxter International Inc., BioNTech SE, ImmunoGen Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare Limited, Sandoz International GmbH, Lundbeck A/S, Pfizer Inc., and others.
The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.